Hepatitis C Community
Telaprevir Demonstrates Antiviral Activity in Genotype 2 Not Genotype...
About This Community:

This forum is for questions about medical issues and research aspects of Hepatitis C such as, questions about being newly diagnosed, questions about current treatments, information and participation in discussions about research studies and clinical trials related to Hepatitis. If you would like to communicate with other people who have been touched by Hepatitis, please visit our new Hepatitis Social/Living with Hepatitis forum

Font Size:
A
A
A
Background:
Blank
Blank
Blank
Blank Blank

Telaprevir Demonstrates Antiviral Activity in Genotype 2 Not Genotype 3 HCV

http://www.clinicaloptions.com/Hepatitis/Journal%20Options/Collections/2011%20JO%20Hepatitis%20Volume%205/Articles/Foster_Gastroenterology_2011/Slideset.aspx
Related Discussions
2 Comments Post a Comment
Blank
163305_tn?1333672171
I couldn't bring the link up but as a geno 2, I'm glad not to be doing teleprivir.
And with genotype 2 doing so well with the new oral treatment, why do the triple therapy?
Blank
Avatar_m_tn
Hi desrt, this was on the expert commentary part... Hope all is well.

Use of Telaprevir in Genotype 2 or 3 HCV—Not Likely
Mitchell L. Shiffman, MD
Posting Date: December 13, 2011
Director, Liver Institute of Virginia
Bon Secours Virginia Health System
Richmond and Newport News, Virginia

Telaprevir works very effectively against hepatitis C virus (HCV) genotype 1 infection, and a wealth of data support this fact.[1-5] By contrast, there are very few data about the efficacy of telaprevir in HCV genotypes 2 and 3, particularly in combination with peginterferon/ribavirin.

To shed light on this issue, Foster and colleagues[6] conducted a randomized phase IIa study in patients chronically infected with HCV genotype 2 or 3 to determine whether the addition of telaprevir to peginterferon/ribavirin enhanced the rates of sustained virologic response (SVR).[6] In total, 26 patients with HCV genotype 2 (23 were treated) and 26 patients with HCV genotype 3 infection were randomly assigned to receive 15 days of telaprevir, telaprevir plus peginterferon/ribavirin, or peginterferon/ribavirin, all followed by peginterferon/ribavirin for 22-24 weeks.

Unfortunately, the results of this study were somewhat disappointing. There was additive efficacy with telaprevir in patients with HCV genotype 2 infection. For example, the kinetics of virologic suppression occurred earlier and was deeper with the addition of telaprevir to peginterferon/ribavirin vs peginterferon/ribavirin alone (eg, median HCV RNA change at Day 3: -4.03 vs -2.04 log10 IU/mL; median HCV RNA change at Day 15: -5.51 vs -4.83 log10 IU/mL). All 5 patients who received telaprevir/peginterferon/ribavirin triple therapy attained SVR compared with 8 of 9 patients assigned to peginterferon/ribavirin control (100% vs 89%). One must recognize, however, that infection with HCV genotype 2 has the highest cure rate of all HCV genotypes when treated with peginterferon/ribavirin. Thus, despite having some antiviral activity against this type of HCV, the addition of telaprevir to peginterferon/ribavirin really has very little impact on overall SVR in this patient population.

Blank
Post a Comment
To
Blank
Weight Tracker
Weight Tracker
Start Tracking Now
Hepatitis C Community Resources
RSS Expert Activity
469720_tn?1388149949
Blank
Abdominal Aortic Aneurysm-treatable... Blank
Oct 04 by Lee Kirksey, MDBlank
242532_tn?1269553979
Blank
The 3 Essentials to Ending Emotiona...
Sep 18 by Roger Gould, M.D.Blank
242532_tn?1269553979
Blank
Control Emotional Eating with this ...
Sep 04 by Roger Gould, M.D.Blank
Top Hepatitis Answerers
446474_tn?1404424777
Blank
HectorSF
CA
1815939_tn?1377995399
Blank
pooh55811
476246_tn?1418874514
Blank
Marcia2202
Copenhagen, Denmark
317787_tn?1373214989
Blank
Dee1956
DC
163305_tn?1333672171
Blank
orphanedhawk
Rural Mural, CA
96938_tn?1189803458
Blank
FlGuy
South, FL